Mohamamd ALABBAS

Dr. Mohamamd ALABBAS

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
MAMohamamd ALABBAS
Mohamamd ALABBAS
HKHamza Khoudari
Hamza Khoudari
GGGaurav Ghosh
Gaurav Ghosh
OSOmar T. Sims
Omar T. Sims
DWDavid Wan
David Wan
Background: Achalasia is a debilitating esophageal motility disorder characterized by absent peristalsis and incomplete relaxation of the lower esophageal sphincter (LES). Myotomy procedures—primarily peroral endoscopic myotomy (POEM) and laparoscopic Heller myotomy (LHM)—aim to reduce LES pressure and alleviate dysphagia. The functional lumen imaging probe (FLIP) measures real-time changes in esophagogastric junction (EGJ) compliance and distensibility during myotomy. We conducted a systematic review and meta-analysis of peer-reviewed literature on the use of preprocedural and intraprocedural FLIP in guiding myotomy adequacy and their impact on clinical outcomes. Methods: We conducted a systematic review and meta-analysis adhering to PRISMA and Cochrane guidelines. Literature searches (PubMed, Scopus, Cochrane CENTRAL, Web of Science, Google Scholar) were performed through December 2023. We included studies (N = 21) assessing FLIP use in achalasia patients undergoing POEM or LHM. Primary outcomes included FLIP measures (distensibility index [DI], cross-sectional area [CSA], diameter [Dmin]) and clinical outcomes (Eckardt score improvement, reflux esophagitis). Results: A total of 1455 patients were analyzed (mean age 52.3 years; 52.8% male). Both POEM and LHM led to significant increases in DI, CSA, and Dmin at 40 mL FLIP distension (mean differences of 4.69, 100.35, and 4.90, respectively; p < 0.001). Eckardt scores significantly decreased after myotomy (MD = − 5.40; 95% CI − 5.91 to − 4.88), with POEM yielding a larger reduction than LHM (p = 0.03). Reflux esophagitis occurred in 28% of patients overall—31% following POEM versus 11% following LHM. Intraoperative FLIP was associated with lower esophagitis rates compared to preoperative FLIP use (26% vs. 46%, p < 0.05). Conclusions: FLIP-guided myotomy improves objective EGJ distensibility metrics and aligns with enhanced symptom relief in achalasia. POEM offers greater Eckardt score reductions but carries a higher risk of reflux esophagitis than LHM. Future prospective studies should standardize FLIP protocols, define optimal DI cutoffs, and assess long-term outcomes to further refine achalasia management.

7 December 2023 in Gastro Hep Advances
Verified
Journal Article
Open access
MAMohamamd ALABBAS
Mohamamd ALABBAS
ACAbdelkader Chaar
Abdelkader Chaar
CGCheryl A. Gibson
Cheryl A. Gibson
MAMohamad Alhoda Mohamad Alahmad
Mohamad Alhoda Mohamad Alahmad
Cachexia is a metabolic syndrome defined by a loss of more than 5% of body weight in patients with chronic diseases. The goal of this study was to investigate the link between cirrhotic cachexia and hospital mortality and the 30-day risk of all-cause readmission. The study utilized Nationwide Readmission Database for the years 2016–2019 in which all patients older than 18 year old with a primary diagnosis of cirrhosis were included. We excluded patients with a concurrent diagnosis of Human Immunodeficiency Virus, chronic lung disease, end-stage renal disease, malignancy, heart failure, and certain neurological diseases. We compared baseline characteristics and outcomes between those who were cachectic and those who were not. Survey multivariate logistic regression was used to analyze the independent impact of cachexia on categorical outcomes. The study cohort was 342,030 cases. Cachexia was identified in approximately 17% of the study population (58,509 discharges). The mean age was 56 years. Slightly more female patients noted in cachexia group (41% vs 38%). Inpatient mortality during index hospitalization were higher in patients with cirrhotic cachexia (6.7% vs 3%, P < .01). Inpatient mortality during first all-cause readmission within 30 days of index discharge was also higher in cachexia group (8.6% vs 6.5%, P < .01). Cachexia is an adverse prognosticator for inpatient outcomes in patients with cirrhosis. It is associated with greater readmission rates, inpatient mortality, and prolonged hospital admissions.

3 June 2025 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
MAMohamamd ALABBAS
Mohamamd ALABBAS
HKHamza Khoudari
Hamza Khoudari
GGGaurav Ghosh
Gaurav Ghosh
OSOmar T. Sims
Omar T. Sims
DWDavid Wan
David Wan

22 May 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
BEBaila Elkin
Baila Elkin
MAMohamamd ALABBAS
Mohamamd ALABBAS
QYQijun Yang
Qijun Yang
BBBlake Brandon
Blake Brandon
CCChristopher Coppa
Christopher Coppa
JWJamile Wakim-Fleming
Jamile Wakim-Fleming
Background Sarcopenia after liver transplantation is poorly characterized in recipients with metabolic dysfunction-associated steatotic liver disease (MASLD) and severe obesity. We evaluated longitudinal changes in psoas muscle index (PMI) after transplantation and examined whether PMI trajectory was associated with post-transplant survival. Methods We performed a retrospective single-center study of adults with MASLD and body mass index ≥ 35 kg/m2 who underwent orthotopic liver transplantation between January 2015 and June 2023. PMI was measured on computed tomography at the L3 level before transplantation and at 6 months, 1 year, 3 years, and 5 years when available. Longitudinal change was assessed using linear mixed-effects models adjusted for survival status. Survival analyses included Kaplan–Meier estimation and univariate logistic regression. Results Seventy-three recipients were included; mean age was 59.3 years, 50.7% were women, median body mass index was 38.1 kg/m2, and mean Model for End-Stage Liver Disease score was 23.6. PMI declined significantly from baseline to 6 months (β = − 0.60, 95% confidence interval [CI] − 0.98 to − 0.22; p = 0.002) and 1 year (β = − 0.46, 95% CI − 0.83 to − 0.09; p = 0.015), with persistent reduction at 3 years. Survivors showed modest early decline followed by relative stabilization, whereas non-survivors demonstrated steeper decline. However, pre-transplant PMI, 6-month PMI, and early PMI change were not significantly associated with mortality. Conclusions In liver transplant recipients with MASLD and severe obesity, muscle loss worsens during the first post-transplant year and may persist thereafter. These findings raise questions regarding optimal timing of nutritional and physical rehabilitation and justify larger studies to determine the prognostic significance of post-transplant muscle trajectories.

11 June 2026 in Journal of Dual Diagnosis
Verified
Journal Article
Closed access
MAMohamamd ALABBAS
Mohamamd ALABBAS
YGYuqi Guo
Yuqi Guo
JSJingyi Shi
Jingyi Shi
HWHongke Wu
Hongke Wu
WMWalaa Mahmoud
Walaa Mahmoud
OSOmar T. Sims
Omar T. Sims
Concurrent alcohol use and smoking exert super-additive toxic effects that accelerate hepatic injury in people living with hepatitis C (HCV). Objectives of this study were to estimate the prevalence of concurrent alcohol use and active smoking at the population-level over the last decade among adults living with HCV in the United States (U.S.), examine trends in the prevalence of concurrent alcohol use and active smoking, and to identify risk factors associated with concurrent alcohol use and active smoking. We conducted a repeated cross-sectional analysis using six NHANES cycles (2007-2018). The study population included adults aged ≥20 years with current HCV infection, defined as detectable HCV RNA with confirmatory anti-HCV seropositivity, and complete data on alcohol use and smoking status. Analyses incorporated NHANES' complex survey design (strata, primary sampling units, and MEC examination weights). Prevalence estimates and temporal trends were derived using design-based methods, with linear regression applied to test for trends. Associations were examined using design-adjusted multinomial logistic regression to calculate adjusted odds ratios (aORs). The pooled, survey-weighted prevalence of concurrent alcohol use and active smoking among adults living with HCV in the U.S. between 2007 and 2018 was 39.5%. Trends in the prevalence of concurrent alcohol use and active smoking did not decrease but instead remained relatively high over the 11-year period (Trend P = 0.71). In multivariate analysis, current marijuana use (aOR = 2.88, 95% CI 2.84-2.92), lifetime substance use (aOR = 5.98, 95% CI 5.87-6.10), depression (aOR = 2.59, 95% CI 2.55-2.63), and a history of cancer (aOR = 1.50, 95% CI 1.45-1.54) were positively associated with concurrent alcohol use and active smoking. Markedly high and non-decreasing rates of concurrent alcohol use and active smoking at the population-level may contribute to higher incident cases of HCV-related morbidity and mortality in the near future.

8 September 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
MAMohamamd ALABBAS
Mohamamd ALABBAS
AAAkram Alnounou
Akram Alnounou
EIEzzElDien A. Ibrahim
EzzElDien A. Ibrahim
AKAbdulrahman M. Karam
Abdulrahman M. Karam
BBBarbara Balog
Barbara Balog
BNBasile Njei
Basile Njei
Background Whether established statin therapy should be continued after hospitalization for hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis remains uncertain. Methods We performed a retrospective multicenter cohort study in the TriNetX Research network. Adults aged 18–75 years with MASLD cirrhosis, a qualifying inpatient decompensation event, and a statin record before index were classified by whether a statin was recorded from the index date through day 30. Propensity score matching was used to improve balance across demographics, comorbidities, liver-related features, medications, and laboratory values. Outcomes were evaluated through 1 year using platform-generated survival analyses. Results The matched analysis included 1,108 patients (554 per group). At 1 year, statin continuation was not associated with the subsequent decompensation composite (62.1% vs 61.6%; HR 1.08, 95% CI 0.93–1.26) or all-cause mortality (19.7% vs 19.5%; HR 1.04, 95% CI 0.80–1.36). Subsequent ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, the cardiovascular composite, and the muscle and laboratory liver injury composites also did not differ. Liver transplantation was less frequent (2.3% vs 6.1%; HR 0.38, 95% CI 0.20–0.73), whereas all-cause hospitalization was more frequent (62.6% vs 57.8%; HR 1.20, 95% CI 1.03–1.40). Exploratory high-intensity analyses showed higher decompensation, hepatic encephalopathy, and hospitalization. Conclusions Among prevalent statin users with MASLD cirrhosis, continuation after an index decompensation hospitalization was not associated with lower 1-year decompensation or mortality. Isolated secondary and intensity findings are exploratory. Residual confounding, exposure misclassification, competing risk, and overlap between exposure classification and early follow-up limit causal interpretation; prospective and time-aligned studies are needed.